SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.89+1.2%Jan 14 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (10358)2/9/2004 8:32:29 AM
From: Biomaven  Read Replies (1) of 52153
 
<Pipeline problem>

Yes, but...

If you look at small molecule drugs, biotechs can only take full credit for a handful of approved drugs. Many (if not most) late-stage or approved small molecule drugs owned by biotechs were originally developed in big pharma labs and then out-licensed via one route or another.

Reverset, which we've just been talking about is a good example - this was originally a Du Pont drug. There are many other examples. So it's not clear at all that we can shut down the big pharma labs just yet.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News